Long-term disease control in multiple myeloma by in-class transitioning: A commu...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
3 Jul 2020
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour -  MD Anderson Cancer Center, Houston, USA )
3 Jul 2020
Treating acute lymphoblastic leukaemia in the era of COVID-19
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Treating acute lymphoblastic leukaemia in the era of COVID-19 ( Dr Elias Jabbour -  MD Anderson Cancer Center, Houston, USA )
3 Jul 2020
Managing acute myeloid leukaemia during the COVID-19 pandemic
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Managing acute myeloid leukaemia during the COVID-19 pandemic ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
1 Jul 2020
Gut microbiome disturbance by antibiotic treatment early in life is sufficient t...
Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Sala...
Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice ( Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Salamanca, Spain )
30 Jun 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
26 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020